Author
Year
(ref)
|
Type of article
|
No. of cases (mean age)
|
Methods
|
Relevant results
|
Association
(Level of evidence)
|
Karevold et al. 2006 (21)
|
Cross-sectional survey.
|
N= 5125 (10 yr).
|
Assess co-morbidity and risk factors for recurrent upper and lower
respiratory infections.
|
Atopic disease was a constitutional risk factor, for upper and lower
airway infections.
|
Yes
(Level IV)
|
Ciprandi et al. 2009 (22)
|
Prospective study.
|
N=117 (4.02 ± 1.0yr); 46 allergic.
|
Evaluate the number and duration of respiratory infections (RI) in
allergic and non-allergic children.
|
Allergic children showed a significantly higher number (mean 1.26 +/-
0.73) and longer duration of RI (8.92 days) in comparison with
non-allergic group (0.94 +/- 1.37 and 4.85 days).
|
Yes
(Level II)
|
Kværner et al. 1996 (23)
|
Retrospective analysis.
|
N= 7992 (mean age not known)
|
Estimate comorbidity between ear infections, tonsillitis, sinusitis and
related childhood diseases
|
The correlation between the infectious and atopic diseases were
weak.
|
Inconclusive
(Level IV)
|
Sütçü et al. 2016 (24)
|
Retrospective analysis.
|
N= 507 children (46, range 4-190, months)
|
Evaluate children presenting with the complaint of recurrent infections
and to determine the possible predictive factors.
|
Atopic children had longer episodes of recurrent URTI compared to
controls; however, the number of episodes per year was not significantly
different.
|
No
(Level IV)
|
Role of anti-allergy treatment in preventing upper respiratory
infections. |
Role of anti-allergy treatment in preventing upper
respiratory infections. |
Role of anti-allergy treatment in preventing
upper respiratory infections. |
Role of anti-allergy treatment in
preventing upper respiratory infections. |
Role of anti-allergy
treatment in preventing upper respiratory infections. |
Role of
anti-allergy treatment in preventing upper respiratory
infections. |
Ciprandi 1999 (22)
|
Double-blind and placebo-controlled study.
|
N= 20 children with allergy;
10 terfendine group (8.5±3 yr); 10 placebo
(7.9±2.7 yr).
|
Continuous terfenadine (1 mg/kg per body weight per day) vs placebo for
1 year. Outcome: Symptoms; inflammatory cells and ICAM-1 measured by
nasal scraping.
|
Terfenadine treatment reduce ICAM-1 expression on nasal epithelial
cells; children treated with terfenadine had significantly fewer extra
visits and school absences than the placebo group.
|
Yes
(Level I)
|
Fasce 1996 (16)
|
Double-blind, placebo controlled randomized study.
|
N= 20 children (5-14 years old) with mite allergy.
|
Cetirizine vs placebo for 15 days. Nasal scrapings were performed to
evaluate inflammatory cell infiltration and ICAM-I expression on
epithelial cells.
|
Cetirizine-treated children showed a significant reduction (or even
total absence) of ICAM-I expression on epithelial cells (p=0.002) and a
reduction trend in inflammatory cell counts compared with placebo
|
Yes
(Level I)
|
Barebri et al 2015 (27)
|
Prospective case control observational stydy, not-randomised.
|
N=40 HDM allergic children (9.3 yr)
|
Patients were subdivided in 2 groups: 20 treated by symptomatic drugs
and 20 by high-dose HDM-SLIT.
|
SLIT-treated children had significantly (p = 0.01) less RI episodes
(3.5) than control group (5.45).
|
Yes
(Level II)
|
Barberi 2018 (26)
|
Retrospective analysis.
|
N= 33 HDM allergic children (9.3 yr).
|
Investigate whether 3 year high-dose HDM-SLIT affects respiratory
infections in children with allergic rhinitis.
|
SLIT-treated children had significantly fewer RI episodes than
symptomatically treated children. In addition, they had less fever and
took fewer medications, such as antibiotics and antipyretics.
|
Yes
(Level IV)
|